Last reviewed · How we verify
bimatoprost 15 µg generation 2
bimatoprost 15 µg generation 2 is a Small molecule drug developed by Allergan. It is currently in Phase 1 development.
At a glance
| Generic name | bimatoprost 15 µg generation 2 |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bimatoprost 15 µg generation 2 CI brief — competitive landscape report
- bimatoprost 15 µg generation 2 updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about bimatoprost 15 µg generation 2
What is bimatoprost 15 µg generation 2?
bimatoprost 15 µg generation 2 is a Small molecule drug developed by Allergan.
Who makes bimatoprost 15 µg generation 2?
bimatoprost 15 µg generation 2 is developed by Allergan (see full Allergan pipeline at /company/allergan).
What development phase is bimatoprost 15 µg generation 2 in?
bimatoprost 15 µg generation 2 is in Phase 1.
Related
- Manufacturer: Allergan — full pipeline
- Compare: bimatoprost 15 µg generation 2 vs similar drugs
- Pricing: bimatoprost 15 µg generation 2 cost, discount & access